October 26, 2020 07:00 AM EDTUpdated 10:59 AM

Covid-19 roundup: AstraZeneca's candidate could elicit immune response in older patients; The EMA could approve a vaccine with less than 50% efficacy — report

Nicole DeFeudis

Editor

With permission to resume its Covid-19 trial in the US, AstraZeneca is back in the race for emergency approval. And early results suggest the candidate …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Covid-19 roundup: AstraZeneca's candidate could elicit immune response in older patients; The EMA could approve a vaccine with less than 50% efficacy — report

Nicole DeFeudis

Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Will CRISPR matter?

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Covid-19 roundup: As­traZeneca's can­di­date could elic­it im­mune re­sponse in old­er pa­tients; The EMA could ap­prove a vac­cine with less than 50% ef­fi­ca­cy — re­port

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Covid-19 roundup: AstraZeneca's candidate could elicit immune response in older patients; The EMA could approve a vaccine with less than 50% efficacy — report